Palvella Therapeutics (PVLA) Current Deferred Revenue (2013 - 2023)

Palvella Therapeutics (PVLA) has 9 years of Current Deferred Revenue data on file, last reported at $3.5 million in Q3 2023.

• Current Deferred Revenue for Q3 2023 came in at $3.5 million, up 400.0% year-over-year; the trailing twelve-month figure through Sep 2023 was $3.5 million (up 400.0% YoY), and the FY2022 annual result was $20.8 million, down 17.09% from the prior year.
• Current Deferred Revenue declined to $3.5 million in Q3 2023 per PVLA's latest filing, from $4.7 million in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $28.4 million in Q2 2019 and troughed at $700000.0 in Q3 2022.
• A 5-year average of $17.4 million and a median of $20.8 million in 2022 frame the typical range for Current Deferred Revenue.
• The sharpest annual moves came in 2022 and 2023: Current Deferred Revenue plunged 97.35% in 2022, then surged 400.0% in 2023.
• A 5-year view of Current Deferred Revenue shows it stood at $11.3 million in 2019, then climbed by 12.18% to $12.6 million in 2020, then jumped by 98.91% to $25.1 million in 2021, then dropped by 17.09% to $20.8 million in 2022, then plunged by 83.19% to $3.5 million in 2023.
• Business Quant data shows PVLA's Current Deferred Revenue at $3.5 million in Q3 2023, $4.7 million in Q2 2023, and $26.7 million in Q1 2023.